WebJan 11, 2024 · The FDA has granted orphan drug designation to Cytokinetics' (NASDAQ:CYTK) CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy (HCM).Among the benefits... WebNov 16, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data for CK-3773274 (CK-274) and CK-3772271 (CK-271) were ...
Cytokinetics: CK-274 Receives Orphan Drug Designation
WebJul 19, 2024 · -- Cytokinetics on Monday reported positive results from cohorts 1 and 2 of the mid-stage trial of CK-274, an investigational next-generation cardiac myosin inhibitor in development for the... April 9, 2024 WebSep 23, 2024 · SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered by … girl scout badges 2023
Cytokinetics (CYTK) Not Expecting REMS for CK-274 - Mizuho
WebDec 9, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) … WebCytokinetics Clinical Study: REDWOOD-HCM (CY 6021) STUDY OBJECTIVES: STUDY DESIGN: Primary Endpoint: • Assess the safety and tolerability of CK-274 Secondary Endpoint: • Assess the PK and PD of CK-274, guided by echocardiography, with two-week dose titration Inclusion Criteria: • Males and females between 18 and 70 years of age at … WebApr 12, 2024 · Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops … funeral flower keepsake ideas diy